Vyhledávejte léky rychleji. Vyzkoušejte interakce.
Vyhledávejte léky rychleji. Vyzkoušejte interakce.
Přihlášení
Registrace
Geneva Score for VTE Prophylaxis

Geneva Score for VTE Prophylaxis

Identification of acutely ill medical patients requiring thromboprophylaxis

Low risk
VTE prophylaxis generally not recommended
NaN

Další informace

Vytisknout nebo uložit jako PDF
Instrukce a reference

Upozornění

Tento nástroj slouží pouze pro vzdělávací účely a nepředstavuje odborné poradenství ani odborné poradenství nenahrazuje. Tento nástroj není určen k lékařské diagnostice nebo léčbě.
General description
Venous thromboembolism (VTE) is one of the most common cardiovascular diseases and about 50% of all VTE events occur as a result of a hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures reducing the rate of symptomatic VTE by half.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.

Result ranges

Low risk
VTE prophylaxis generally not recommended
0–3
High risk
VTE prophylaxis generally recommended
≥ 3

Formula

Cardiac failure, respiratory failure, recent stroke, recent myocardial infarction, acute infection/sepsis, acute rheumatic disease, active malignancy, myeloproliferative syndrome, nephrotic syndrome, history of VTE, known thrombophilia are assigned 2 points if they are answered yes. The rest are assigned 1 point if answered yes. All questions are assigned 0 points if answered no.

References

Chopard, P et al. “Identifying acutely ill medical patients requiring thromboprophylaxis.” Journal of thrombosis and haemostasis : JTH vol. 4,4 (2006): 915-6. doi:10.1111/j.1538-7836.2006.01818.x
Nendaz, M et al. “Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE).” Thrombosis and haemostasis vol. 111,3 (2014): 531-8. doi:10.1160/TH13-05-0427

Verze

1

O tomto nástroji

Venous thromboembolism (VTE) is one of the most common cardiovascular diseases and about 50% of all VTE events occur as a result of a hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures reducing the rate of symptomatic VTE by half.
Geneva Risk Score is one of the risk assessment models developed for identifying hospitalised medical patients at increased risk of VTE. It consists of 19 variables and a points-based system that enables stratification of patients into high and low VTE risk and can thus help inform decisions on prescription of thromboprophylaxis; however, decisions on thromboprophylactic interventions should also be based on assessment of bleeding risk.
Geneva Risk Score has been externally validated and compared favourably with the Padua Prediction Score, particularly for its accuracy in identifying low-risk patients who do not require thromboprophylaxis.
Drugs app phone

Používejte aplikaci Mediately

Získávejte informace o léčivech rychleji.

Naskenujte kód pomocí fotoaparátu v mobilu.
4.9

Více než 36k hodnocení

Používejte aplikaci Mediately

Získávejte informace o léčivech rychleji.

4.9

Více než 36k hodnocení

Stáhnout

Jděte dál než jen k informacím o lécích s PRO

Řešte interakce, zobrazujte si omezení použití a najděte všechny ostatní odpovědi s Vaší AI asistentkou Elly.

Preveri, kaj ponuja PRO
Používáme cookies Soubory cookie nám pomáhají poskytovat to nejlepší uživatelské prostředí na našich webových stránkách. Používáním našich stránek souhlasíte s používáním cookies. Více o tom, jak používáme soubory cookie, naleznete v našich Zásadách používání souborů cookie.